- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-1-1-mer
- Ligands
- 6 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.7: 1 residues within 4Å:- Chain A: N.1134
Ligand excluded by PLIPNAG.8: 2 residues within 4Å:- Chain A: E.1072, N.1074
Ligand excluded by PLIPNAG.9: 3 residues within 4Å:- Chain A: N.801, S.803, Q.804
Ligand excluded by PLIPNAG.10: 3 residues within 4Å:- Chain A: N.709, G.1131
- Chain C: D.796
Ligand excluded by PLIPNAG.11: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.12: 1 residues within 4Å:- Chain A: N.616
Ligand excluded by PLIPNAG.13: 2 residues within 4Å:- Chain A: N.603, T.604
Ligand excluded by PLIPNAG.14: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.15: 1 residues within 4Å:- Chain A: N.282
Ligand excluded by PLIPNAG.16: 2 residues within 4Å:- Chain B: Y.28, N.61
Ligand excluded by PLIPNAG.17: 1 residues within 4Å:- Chain B: N.282
Ligand excluded by PLIPNAG.18: 1 residues within 4Å:- Chain B: N.603
Ligand excluded by PLIPNAG.19: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain B: S.708, N.709
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain B: N.801, Q.804
Ligand excluded by PLIPNAG.22: 2 residues within 4Å:- Chain B: E.1072, N.1074
Ligand excluded by PLIPNAG.23: 1 residues within 4Å:- Chain B: N.1134
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain B: N.164, N.165
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain B: N.331, Q.580
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain B: G.339, F.342, N.343
Ligand excluded by PLIPNAG.27: 4 residues within 4Å:- Chain C: Q.115, N.165, C.166, T.167
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain C: E.281, N.282
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain C: N.603
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain C: N.616, T.618
Ligand excluded by PLIPNAG.31: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain C: N.709
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain C: N.801, S.803, Q.804
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain C: E.1072, N.1074
Ligand excluded by PLIPNAG.35: 1 residues within 4Å:- Chain C: N.1134
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cerutti, G. et al., Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure (2021)
- Release Date
- 2021-03-17
- Peptides
- Spike glycoprotein: ABC
Fab 2-7 variable light chain: D
Fab 2-7 variable heavy chain: E - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
LE
H
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-1-1-mer
- Ligands
- 6 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cerutti, G. et al., Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure (2021)
- Release Date
- 2021-03-17
- Peptides
- Spike glycoprotein: ABC
Fab 2-7 variable light chain: D
Fab 2-7 variable heavy chain: E - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
LE
H